quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:00·108d
PRRelease
Bright Minds Biosciences Inc. logo

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

DRUG· Bright Minds Biosciences Inc.
Health Care
Original source

Companies

  • DRUG
    Bright Minds Biosciences Inc.
    Health Care

Recent analyst ratings

  • Apr 13UpdateJefferies$145.00
  • Sep 8UpdateBTIG Research$72.00
  • May 13UpdateTD Cowen-
  • May 7UpdateChardan Capital Markets$80.00
  • Jan 23UpdatePiper Sandler$93.00
  • Jan 10UpdateCantor Fitzgerald-

Related

  • ANALYST11d
    Jefferies initiated coverage on Bright Minds Biosciences with a new price target
  • PR57d
    Bright Minds Biosciences to Present at Upcoming Conferences
  • SEC65d
    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
  • SEC65d
    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
  • SEC70d
    SEC Form 6-K filed by Bright Minds Biosciences Inc.
  • SEC76d
    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
  • SEC104d
    SEC Form 6-K filed by Bright Minds Biosciences Inc.
  • PR104d
    Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022